Nasdaq · CIK 0001159036 · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
HALOZYME THERAPEUTICS, INC.
HALO chart by TradingView
PRICE HISTORY
LIVE · NASDAQHALO chart by TradingView
- REVENUE FY2025 ENDED DEC 2025
- $1.4B
- EBITDA
- $0.5B
- FREE CASH FLOW
- $0.6B
- EPS
- $2.56
- GROSS MARGIN
- 83.62%
- ROIC
- 15.40%
Q2 FY26ENDED JUN 2026HOVERDRAG ACROSS ANY CHART TO SCRUB ALL 24 · 40 QUARTERS SHOWNVALUATIONGROWTHPROFITABILITY & RETURNSCASH & CAPITALBALANCE SHEET
VALUATION
what you pay for a unit of the business7 CHARTS⤢
P / E RATIO (TTM)
22.9x
-50%11.6x173.5x
⤢
P / SALES (TTM)
5.7x
-41%5.3x22.7x
⤢
P / BOOK
66.1x
+92%8.5x168.7x
⤢
EV / EBITDA (TTM)
18.7x
-47%11.4x106.6x
⤢
EV / REVENUE (TTM)
6.9x
-35%6.5x23.6x
⤢
FCF YIELD (TTM)
8.50%
+12.0pp-4.23%8.50%
⤢
DIVIDEND YIELD (TTM)
—
GROWTH
is the business getting bigger5 CHARTS⤢
REVENUE
$0.5B
+1410%⤢
EBITDA (DERIVED)
$0.3B
+$0.3B⤢
NET INCOME
$0.2B
+$0.3B⤢
EPS (DILUTED)
$1.90
+$2.12⤢
REVENUE GROWTH YOY
47.67%
-5.6pp-68.23%386.02%
PROFITABILITY & RETURNS
what survives to the bottom, and what it earns on capital4 CHARTS⤢
FCF MARGIN
49.21%
+78.0pp-76.29%104.67%
⤢
RETURN ON CAPITAL
19.44%
+70.8pp-105.22%61.46%
⤢
RETURN ON EQUITY (TTM)
288.13%
+494.4pp-206.30%649.18%
MARGIN FUNNEL
every line is a share of the same revenue, so they read on one scale — the gaps are what each layer takes out, and net rises above operating when income arrives from outside the businessGROSS MARGIN83.54%
OPERATING MARGIN59.80%
NET MARGIN47.80%
FCF MARGIN49.21%
CASH & CAPITAL
where the money actually goes5 CHARTS⤢
FREE CASH FLOW
$0.2B
+$0.2B⤢
STOCK-BASED COMP
$0.0B
+166%⤢
CAPITAL EXPENDITURE
$0.0B
+884%⤢
SHARES OUTSTANDING
0.12B
-5%⤢
DIVIDEND / SHARE
—
BALANCE SHEET
how much cushion there is3 CHARTS⤢
CASH & EQUIVALENTS
$0.2B
+167%⤢
TOTAL DEBT
$2.1B
+912%⤢
DEBT / EBITDA (TTM)
3.5x
+44%1.8x10.3x
OWNERSHIP
10 LARGEST HOLDERS · WHO OWNS THE FLOATINSTITUTIONS 114.38%INSIDERS 1.11%OTHER / RETAIL 0.00%907 INSTITUTIONAL FILERS
| HOLDER | % HELD | SHARES | VALUE | CHANGE |
|---|---|---|---|---|
| Blackrock Inc. | 11.18% | 13.3M | $1.37B | +0.9% |
| Vanguard Capital Management LLC | 4.44% | 5.3M | $543.6M | NEW |
| Vanguard Portfolio Management LLC | 4.43% | 5.2M | $541.3M | NEW |
| State Street Corporation | 4.16% | 4.9M | $509.2M | -3.6% |
| Invesco Ltd. | 3.38% | 4.0M | $413.8M | +10.0% |
| Bank of America Corporation | 2.46% | 2.9M | $300.4M | +6.6% |
| Boston Partners | 2.34% | 2.8M | $286.0M | +3.4% |
| Morgan Stanley | 2.16% | 2.6M | $264.2M | -3.6% |
| William Blair Investment Management, LLC | 2.13% | 2.5M | $260.5M | +37.1% |
| Geode Capital Management, LLC | 2.11% | 2.5M | $258.4M | +3.0% |
AS OF 2026-03-31 · MOST RECENT 13F FILINGS
SOURCE → 10-K · 10-Q · 8-K / GUIDANCE · ALL FILINGS
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.
FILING DATA AS OF 2026-08-10. Figures are derived from public SEC EDGAR filings (40most recent quarters shown, Q4 implied as full-year minus Q1-Q3). Valuation multiples use each period’s fiscal period-end close. Live price charts and quotes are provided by TradingView. This page is informational only — it is not investment advice, and figures are not warranted for accuracy. EBITDA is not a GAAP measure; it is derived as operating income + D&A. Verify against the linked source filing before relying on any number here.